T1 Organism 96 103 patient
T2 Protein 1072 1076 JAK1
T3 Condition 417 436 metastatic melanoma
T4 Condition 949 957 mutation
T5 Biomarker 1388 1392 PD-1
T6 Organism 1419 1427 patients
T7 Organism 1419 1426 patient
T8 Condition 676 692 resistant tumors
T9 Condition 775 783 mutation
T11 Gene 792 796 gene
T12 Gene 863 877 Janus kinase 2
T13 Protein 1237 1240 B2M
T14 Organism 717 724 patient
T15 Biomarker 79 83 PD-1
T16 Protein 1032 1035 B2M
T17 Protein 1081 1085 JAK2
T18 Organism 717 725 patients
T20 Condition 110 118 melanoma
T21 Organism 96 104 patients
T22 Condition 217 222 tumor
T23 Protein 1141 1157 interferon gamma
T24 Condition 1252 1260 mutation
T25 Protein 983 1030 antigen-presenting protein beta-2-microglobulin
T26 Protein 854 858 JAK1
T27 Condition 1433 1441 melanoma
T28 Gene 918 934 wild-type allele
T29 Condition 686 691 tumor
T30 Organism 403 410 patient
T31 Protein 597 608 Whole-exome
T32 Condition 1097 1106 mutations
T33 Gene 807 852 interferon-receptor–associated Janus kinase 1
T34 Gene 965 969 gene
T35 Level 1219 1231 cancer cells
T36 Gene 54 77 anti–programmed death 1
T37 Organism 403 411 patients
T38 Protein 736 757 resistance-associated
T39 Intervention 337 351 biopsy samples
T40 Condition 775 784 mutations
T41 Gene 792 797 genes
T42 Gene 902 910 deletion
T43 Organism 1063 1070 patient
T44 Protein 879 883 JAK2
T45 Gene 807 826 interferon-receptor
T46 Gene 1498 1517 interferon-receptor
T47 Condition 1097 1105 mutation
T48 Gene 502 511 anti–PD-1
T49 Condition 470 475 tumor
T50 Condition 377 394 relapsing lesions
